TC
ESPR

T3 Companies’s Esperion Therapeutics ESPR Stock Holding History

T3 Companies’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Buy
+82,500
New +$231K 0.28% 71

Other funds holding ESPR

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $112M AUM 76.54% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

T3 Companies's ESPR Position: Q2 2026 in Review

T3 Companies opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 82,500 shares worth $261K. The stake represents 0.28% of the portfolio and ranks #71 among its holdings.

41 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • T3 Companies held 82,500 shares of Esperion Therapeutics worth $261K as of Q2 2026.
  • Esperion Therapeutics was a new T3 Companies position in Q2 2026.
  • Esperion Therapeutics made up 0.28% of T3 Companies's portfolio in Q2 2026, its #71 holding.
  • 41 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.